Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of November 2019. The report serves as an update regarding the voluntary delisting of the Company's ordinary shares from the Tel Aviv Stock Exchange (TASE).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement rather than a financial statement.
Material Changes
The primary material change is the scheduled delisting of the Company's ordinary shares from the TASE. The last day of trading on the TASE is set for February 11, 2020, with the official delisting date on February 13, 2020. The Company's American Depositary Shares (ADS) will continue to trade on the Nasdaq Global Market under the symbol "RDHL."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operational outlook, or specific risk factors beyond the delisting event. The delisting is voluntary and conducted in accordance with applicable Israeli law and TASE rules.
Key Facts for Investor Verification
- Ordinary shares will cease trading on the TASE on February 11, 2020.
- Delisting from the TASE is effective February 13, 2020.
- American Depositary Shares (ADS) will remain listed on Nasdaq under symbol "RDHL."
- Each ADS represents 10 Ordinary Shares.
- No financial performance data is included in this specific filing.